IL17A and psoriasis vulgaris: Ixekizumab is a high-affinity, recombinant humanized monoclonal IgG4κ antibody indicated for the treatment of psoriatic arthritis and moderate-to-severe plaque psoriasis by binding specifically to IL-17A and blocking IL-17A activity, reducing inflammation and achieving relief in psoriasis symptoms (78).